Humanized Antihuman IL-6 Receptor Antibody, Tocilizumab
- N. NishimotoAffiliated withLaboratory of Immune Regulation, Graduate School of Frontier Biosciences, Genentech, Inc.
- , T. KishimotoAffiliated withLaboratory of Immune Regulation, Graduate School of Frontier Biosciences, Genentech, Inc.
Interleukin-6 (IL-6) is a pleiotropic cytokine that regulates immune responses and inflammatory reactions. Overproduction of IL-6 has been shown to play a role in inflammatory autoimmune diseases such as rheumatoid arthritis (RA), and juvenile idiopathic arthritis (JIA) and, therefore, an agent blocking IL-6 actions can be a therapy of these diseases. IL-6 belongs to a cytokine family, which shares the cytokine receptor subunit glycoprotein (gp) 130. This family also includes IL-11, oncostatin-M, and leukemia inhibitory factor (LIF). In the IL-6 receptor (IL-6R) system, both a membrane-bound IL-6R and a soluble form of IL-6R are able to mediate IL-6 signals into the cells through the interaction of gp130. Tocilizumab is a humanized antihuman IL-6 receptor antibody designed using genetic engineering technology. Tocilizumab recognizes both the membrane-bound and the soluble form IL-6R and specifically blocks IL-6 actions. Tocilizumab is expected to ameliorate the autoimmune inflammatory diseases with IL-6 overproduction and has been clinically developed as a therapeutic agent for RA, systemic-onset and articular types of JIA, Crohn's disease, etc. Tocilizumab has been shown to be effective not only for improving signs and symptoms but also for preventing joint destruction of RA. Immunopharmacology and clinical benefit of tocilizumab in RA is addressed.
- Humanized Antihuman IL-6 Receptor Antibody, Tocilizumab
- Book Title
- Therapeutic Antibodies
- Book Part
- pp 151-160
- Print ISBN
- Online ISBN
- Series Title
- Handbook of Experimental Pharmacology
- Series Volume
- Series ISSN
- Springer Berlin Heidelberg
- Copyright Holder
- Springer-Verlag Berlin Heidelberg
- Additional Links
- Industry Sectors
- eBook Packages
- Editor Affiliations
- 1. ARC Chair of Rheumatology, Centre Lead Bone & Joint Research Unit, Queen Mary's School of Medicine & Dentistry John Vane Science Centre
- 2. Bone & Joint Research Unit, Queen Mary's School of Medicine & Dentistry John Vane Science Centre
- Author Affiliations
- 3. Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Genentech, Inc., 1–3 Yamadaoka, Suita City, Osaka, 565-0871, Japan
To view the rest of this content please follow the download PDF link above.